YEVOPLO Trademark

Trademark Overview

On Wednesday, March 11, 2020, a trademark application was filed for YEVOPLO with the United States Patent and Trademark Office. The USPTO has given the YEVOPLO trademark a serial number of 88830176. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 2, 2024. This trademark is owned by Bristol-Myers Squibb Company. The YEVOPLO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical...
yevoplo

General Information

Serial Number88830176
Word MarkYEVOPLO
Filing DateWednesday, March 11, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 2, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 2, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical and biological preparations for immunotherapy, including T Cell therapy; cells for medical or clinical use; diagnostic kits consisting primarily of cells for medical or clinical use, all of the foregoing excluding pharmaceutical preparations for treatment of kidney-related diseases and hyperphosphatemia

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, March 17, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Wednesday, June 3, 2020NON-FINAL ACTION WRITTEN
Saturday, March 14, 2020NEW APPLICATION ENTERED
Tuesday, March 17, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 2, 2020ASSIGNED TO EXAMINER
Wednesday, June 3, 2020NON-FINAL ACTION E-MAILED
Wednesday, June 3, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 3, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 3, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, December 4, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, December 30, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 13, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 2, 2021PUBLISHED FOR OPPOSITION
Tuesday, February 2, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, February 25, 2021TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, March 2, 2021EXTENSION OF TIME TO OPPOSE RECEIVED
Thursday, May 13, 2021ASSIGNED TO PETITION STAFF
Tuesday, May 18, 2021CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Sunday, June 13, 2021EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Tuesday, July 27, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, January 19, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, January 19, 2022SOU EXTENSION 1 FILED
Wednesday, January 19, 2022SOU EXTENSION 1 GRANTED
Friday, January 21, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 13, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, July 13, 2022SOU EXTENSION 2 FILED
Wednesday, July 13, 2022SOU EXTENSION 2 GRANTED
Friday, July 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 24, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, January 24, 2023SOU EXTENSION 3 FILED
Tuesday, January 24, 2023SOU EXTENSION 3 GRANTED
Thursday, January 26, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 13, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 13, 2023SOU EXTENSION 4 FILED
Thursday, July 13, 2023SOU EXTENSION 4 GRANTED
Saturday, July 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Monday, September 2, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, September 2, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, January 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU EXTENSION 5 FILED
Monday, January 22, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 22, 2024SOU EXTENSION 5 GRANTED

Related Keywords

yevoplo diseases pharmaceutical preparations disorders anti immune cancer system treatment human